Healthcare technology company Medtronic plc (NYSE:MDT) announced on Wednesday that it has received US Food and Drug Administration (FDA) clearance for its new InPen app, which features missed meal dose detection.

This clearance paves the way for the launch of Medtronic's Smart MDI system, combining the InPen smart insulin pen with the Simplera continuous glucose monitor (CGM).

The system is designed to provide real-time, personalised insulin dosing recommendations, including corrections for missed or inaccurate doses.

Medtronic aims to address a significant unmet need for people with diabetes on multiple daily injections by simplifying diabetes management.